百济神州：2025年净利润扭亏为盈为14.22亿元，百悦泽®全球销售额为280.67亿元 报告期内，百悦泽®的全球销售额为280.67亿元，同比增长48.8%，在BTK抑制剂领域确立了全球领导者地位。整体来 看，公司通过产品收入增长和费用管理提升了经营效率，成功实现盈利。 联影医疗：2025年净利润增长49.6%至18.88亿元，公司持续推出创新产品、提升高端产品市场认可度 近日，百济神州发布公告称，2025年公司营业总收入为382.05亿元，较上年同期的272.14亿元增长40.4%；归母净利润 为14.22亿元，上年同期为-49.78亿元，显示出显著改善。 在业务方面，公司正在推进具有差异化优势的全球管线，包括Zocilurtatugpelitecan（zoci）等多个项目，预计到2026年 底将启动三项注册性研究。2025年全年经营亏损为2.29亿美元，同比减少，亏损减少主要是由于产品收入增长快于运 营开支以及汇兑损失转为汇兑收益。整体来看，公司在多个领域的业务均表现出积极的增长趋势，尤其是在新产品的 推出和市场覆盖的扩展方面。 和铂医药：与SolsticeOncology签订独家授权协议及股权合作协议 ...

【财华社讯】再鼎医药(09688.HK)公布，截至2025年12月31日止年度，总收入约4.6亿美元，同比增长 15.33%；亏损净额约1.76亿美元，同比收窄31.73%；每股亏损0.16美元。 【财华社讯】再鼎医药(09688.HK)公布，截至2025年12月31日止年度，总收入约4.6亿美元，同比增长 15.33%；亏损净额约1.76亿美元，同比收窄31.73%；每股亏损0.16美元。 期内，产品收入净额约4.57亿美元，同比增长15%，产品收入增长主要是由于鼎优乐和纽再乐的销量增 长。 期内，产品收入净额约4.57亿美元，同比增长15%，产品收入增长主要是由于鼎优乐和纽再乐的销量增 长。 ...

在业务方面，公司正在推进具有差异化优势的全球管线，包括Zocilurtatugpelitecan（zoci）等多个项 目，预计到2026年底将启动三项注册性研究。2025年全年经营亏损为2.29亿美元，同比减少，亏损减少 主要是由于产品收入增长快于运营开支以及汇兑损失转为汇兑收益。整体来看，公司在多个领域的业务 均表现出积极的增长趋势，尤其是在新产品的推出和市场覆盖的扩展方面。 （再鼎医药公众号） (编辑：杨燕 林辰) 近日，再鼎医药发布截至2025年12月31日止年度的财务业绩。2025财年公司总收入为4.6亿美元，同比 增长15%。其中，第四季度总收入为1.28亿美元，同比增涨17%。产品收入的增长主要得益于鼎优乐和 纽再乐的销量增加，鼎优乐在2025年第四季度的产品收入净额为1070万美元，较去年同期的330万美元 增长225%。此外，纽再乐的第四季度产品收入净额为1600万美元，较去年同期的1100万美元增长 45%。 在研发支出方面，2025年第四季度的研发支出为6160万美元，较2024年同期的5230万美元有所增加。全 年研发支出为2.21亿美元，较2024年同期的2.35亿美元有所下降，主要得 ...

第四季度产品收入净额为1.271亿美元，2024年同期为1.085亿美元，同比增长17%，按固定汇率(CER)计 算增长 16%;2025年全年产品收入净额为4.572亿美元，2024年同期为3.976亿美元，同比增长15%，按 CER计算同比增长16%。产品收入增长主要是由于鼎优乐和纽再乐的销量增长。 智通财经APP讯，再鼎医药(09688)发布公告，2025年第四季度总收入为1.276亿美元，同比增长 17%;2025年全年总收入为4.602亿美元，同比增长15%。2025年第四季度净亏损为5040.9万美元，同比收 窄38.29%;2025年全年净亏损为约1.755亿美元，同比收窄31.73%。截至2025年12月31日，现金及现金等 价物、短期投资和流动受限制现金总计为7.896亿美元。 2025年第四季度的研发开支为6,160万美元，2024年同期为5,230万美元。2025年全年研发开支为2.209亿 美元，2024年同期为2.345亿美元。第四季度研发开支的增加主要源于临床研究的推进。全年研发开支 下降主要得益于战略资源优化调整带来的人员成本下降。 再鼎医药创始人、董事长兼首席执行官杜莹博士表示 ...

第四季度产品收入净额为1.271亿美元，2024年同期为1.085亿美元，同比增长17%，按固定汇率(CER)计 算增长16%;2025年全年产品收入净额为4.572亿美元，2024年同期为3.976亿美元，同比增长15%，按 CER计算同比增长16%。产品收入增长主要是由于鼎优乐和纽再乐的销量增长。 再鼎医药总裁兼首席运营官Josh Smiley表示："KarXT是再鼎重要的新增长引擎，近期其被纳入了国家 精神分裂症专家共识，凸显了其创新机制及为精神分裂症患者带来有意义影响的潜力，正不断获得更加 广泛的认可。我们正在通过扩大医院覆盖和支持更长的治疗周期，进一步巩固艾加莫德的市场地位。同 时，我们正积极准备TIVDAK的获批上市—这将进一步强化我们在妇瘤领域的管线布局，以及肿瘤电场 治疗用于胰腺癌的潜在获批。展望2026年及未来，新产品上市、潜在适应证拓展以及全球项目的推进， 将助力我们实现未来多年的增长和财务状况的持续改善。" 公告称，亏损净额减少主要是由于产品收入增长快于运营开支以及汇兑损失转为汇兑收益，但被利息收 益减少所抵销。 再鼎医药(09688)发布公告，2025年第四季度总收入为1.276亿美元 ...

2025年第四季度亏损净额为5,040万美元，2024年同期亏损净额为8,170万美元。2025年全年亏损净额为 1.755亿美元，2024年全年亏损净额为2.571亿美元，亏损净额减少主要是由于产品收入增长快于运营开 支以及汇兑损失转为汇兑收益，但被利息收益减少所抵销。 格隆汇2月26日丨再鼎医药(09688.HK)公布2025年第四季度及全年财务业绩。2025年第四季度总收入为 1.276亿美元，2025年全年总收入为4.602亿美元。第四季度产品收入净额为1.271亿美元，2024年同期为 1.085亿美元，同比增长17%，按固定汇率(CER)计算增长16%；2025年全年产品收入净额为4.572亿美 元，2024年同期为3.976亿美元，同比增长15%，按CER计算同比增长16%。产品收入增长主要是由于鼎 优乐和纽再乐的销量增长。 ...

Investment Rating - The report does not explicitly state an investment rating for Zai Lab, but it provides insights into the company's performance and future expectations, which can inform investment decisions. Core Insights - In Q3 2025, Zai Lab reported net product revenue of USD 115 million, representing a year-over-year increase of 13% and a quarter-over-quarter increase of 6% [6] - The company narrowed its net loss to USD 36 million, a 12% improvement from the previous quarter, while adjusted operating loss improved by 18% to USD 28 million [6] - Management has revised the full-year 2025 revenue guidance down to USD 460 million from a previous range of USD 560-590 million [6] Revenue Breakdown - Core product efgartigimod generated sales of USD 27.7 million, up 5% quarter-over-quarter, driven by extended treatment duration and increased market penetration, despite a revenue reduction of approximately USD 2.4 million due to price adjustments [2][8] - Zejula (PARP inhibitor) sales reached USD 42.4 million, a 3% increase quarter-over-quarter [2][8] - Nuzyra (antibiotic) sales were USD 15.4 million, reflecting an 8% quarter-over-quarter increase [2][8] Future Focus - Key milestones anticipated in 2026 include data readouts for Zoci (DLL3 ADC) in the first half of 2026, with registration clinical trials for first-line small cell lung cancer (1L SCLC) and neuroendocrine carcinoma (NEC) expected to start in 2026 [3][8] - Management expects the first overseas approval for an indication in 2027/2028 [3][8] - Other products in the pipeline include ZL-1503 (IL13/IL31) with first-in-human data expected in 2026 and ZL-6201 (LRRC15 ADC) set to initiate global Phase 1 clinical trials in the first half of 2026 [5][8]

Core Viewpoint - Zai Ding Pharma reported a 14% year-on-year increase in total revenue for Q3 2025, reaching $116.1 million, with a narrowed operating loss of $48.8 million, down 28% year-on-year, and an adjusted operating loss reduced by 42% to $28 million. The company has adjusted its full-year revenue guidance for 2025 to at least $460 million [1] Financial Performance - Total revenue for Q3 2025 was $116.1 million, a 14% increase compared to the previous year [1] - Product revenue net amounted to $115.4 million, up 13% from $101.8 million in the same period of 2024, with a 14% increase when adjusted for constant exchange rates [1] - The operating loss was $48.8 million, a reduction of 28% year-on-year, while the adjusted operating loss was $28 million, down 42% [1] Growth Drivers - The revenue growth was primarily driven by increased sales of Zocor and Dingyoule, partially offset by a slowdown in sales of Zele [1] - The company is entering a new growth phase, supported by its commercial capabilities in China and a robust pipeline of global projects [1] Future Outlook - The company is preparing for the upcoming launch of KarXT in the schizophrenia field, while continuing to strengthen the foundation for the launch of Aigamod in the myasthenia gravis area [1] - There is a steady increase in the number of new patients starting treatment and an extension in treatment duration for Aigamod, indicating growing confidence among doctors [1]

Core Insights - Zai Lab (09688) reported a 14% year-over-year increase in total revenue for Q3 2025, reaching $116.1 million, with operating losses narrowing by 28% to $48.8 million, and adjusted operating losses reduced by 42% to $28 million [1][1][1] - The company has adjusted its full-year revenue guidance for 2025 to at least $460 million [1] Revenue Breakdown - Product revenue netted $115.4 million, up 13% from $101.8 million in the same period of 2024, with a 14% increase when calculated at constant exchange rates (CER) [1][1] - Growth was primarily driven by increased sales of Zymeworks and Dingo, partially offset by a slowdown in sales of Zole [1] Management Commentary - The founder and CEO, Dr. Ying Du, stated that Zai Lab is entering a new growth phase, supported by a robust commercialization capability in China and a rapidly advancing global pipeline [1][1] - The company is advancing multiple differentiated global projects, showcasing the speed and scientific rigor of its R&D engine [1] - The President and COO, Josh Smiley, emphasized the strengthening foundation for the launch of Efgartigimod, with increasing new patient numbers and extended treatment durations in the myasthenia gravis field [1][1] - The company is preparing for the anticipated launch of KarXT in the schizophrenia space, while maintaining robust operations and positioning for significant future opportunities [1][1]

Core Insights - Zai Ding Pharma reported a 13% year-over-year increase in product revenue for Q3 2025, reaching $115.4 million, compared to $101.8 million in Q3 2024, with a 14% increase when adjusted for constant exchange rates [1][1][1] Financial Performance - The operating loss for Q3 2025 was $48.8 million, while the adjusted loss, excluding specific non-cash expenses such as depreciation, amortization, and stock-based compensation, was $28 million [1][1] - The net loss for Q3 2025 was $36 million, with a loss per common share of $0.03 (or $0.33 per American Depositary Share), compared to a net loss of $41.7 million in Q3 2024, where the loss per common share was $0.04 (or $0.42 per ADS) [1][1][1] - The reduction in net loss was primarily attributed to increased product revenue and decreased operating expenses [1] Research and Development Expenditure - R&D expenses for Q3 2025 amounted to $47.9 million, down from $66 million in Q3 2024, mainly due to a decrease in licensing fees related to upfront and milestone payments [1][1][1]